Why the study?
Do fixed-dose combination diuretics improve clinical and biochemical responses compared to furosemide alone in patients with congestive heart failure?
Do fixed-dose combination diuretics improve clinical and biochemical responses compared to furosemide alone in patients with congestive heart failure?
Fixed-dose combination diuretics offer no clinical benefits over the single agent furosemide for the treatment of congestive heart failure, while causing significant changes in BUN and renin-aldosterone activity.
Answers are grounded in this paper and cite their sources.
Fixed-dose combinations show no potassium advantage over furosemide in HF; leaves open whether BUN and hormonal shifts affect outcomes.
Thirty-two patients with congestive heart failure were studied for their clinical and biochemical responses to the administration of two combination diuretic products (hydrochlorothiazide/spironolactone and hydrochlorothiazide/triamterene) and the single entity diuretic furosemide. Data from these studies revealed the following: 1. Comparison of the patients on furosemide with those receiving the combination products showed no difference in serum potassium or 24-hour potassium excretion. 2. Significant changes in blood urea nitrogen, plasma renin activity, and urinary aldosterone excretion were noted with both fixed-combination medications but not with furosemide. 3. The combination diuretics offered no clinical benefits over the single agent furosemide. 4. Therapy is best served by the use of a single effective diuretic agent for the treatment of most patients with congestive heart failure.
No takes yet. Share an insight, caveat, or question.
Benjamin Levy (1979) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: